Posted On: 08/24/2015 1:20:02 PM
Post# of 72443
Re: NotRichYet2 #13120
Priority Review Vouchers are given to a company when they get a drug approved in a certain category -- I only knew about the tropical diseases category, did not know about the pediatric disease one.
The voucher is then used for the NEXT drug the company has -- it bumps the next drug they want to have approved up to the front of the line, so it can bump typically 6-8 months (or more) off of the approval process. For a blockbuster drug, this is worth many millions of dollars.
The cool thing is that a company doesn't have to use the voucher itself -- it can sell the voucher, like the sale that was mentioned. So far there have been very few Priority Review Vouchers sold -- so this $350 million figure partially reflects the scarcity. However, even as more companies obtain the vouchers, the value will still stay high -- because Big Pharma will want to use it on their own drugs.
Remember though that the Voucher is issued when a drug is APPROVED -- so it would be several years before CTIX would get a voucher, assuming that Kevetrin works on retinoblastoma.
To me this shows that CTIX is continuing to develop drugs in the most economically feasible way, most beneficial to the shareholders (AND the patients). Going after pediatric retinoblastoma not only helps children survive (hopefully intact, not having an eye removed) but then the funding from the Voucher will help CTIX develop other drugs.
The voucher is then used for the NEXT drug the company has -- it bumps the next drug they want to have approved up to the front of the line, so it can bump typically 6-8 months (or more) off of the approval process. For a blockbuster drug, this is worth many millions of dollars.
The cool thing is that a company doesn't have to use the voucher itself -- it can sell the voucher, like the sale that was mentioned. So far there have been very few Priority Review Vouchers sold -- so this $350 million figure partially reflects the scarcity. However, even as more companies obtain the vouchers, the value will still stay high -- because Big Pharma will want to use it on their own drugs.
Remember though that the Voucher is issued when a drug is APPROVED -- so it would be several years before CTIX would get a voucher, assuming that Kevetrin works on retinoblastoma.
To me this shows that CTIX is continuing to develop drugs in the most economically feasible way, most beneficial to the shareholders (AND the patients). Going after pediatric retinoblastoma not only helps children survive (hopefully intact, not having an eye removed) but then the funding from the Voucher will help CTIX develop other drugs.
(0)
(0)Scroll down for more posts ▼
